# AstraZeneca Imfinzi confirmed overall survival in Phase III CASPIAN trial

- Link: https://www.directorstalkinterviews.com/astrazeneca-imfinzi-confirmed-overall-survival-in-phase-iii-caspian-trial/412809006
- Published: 2020-03-17T07:41:46+00:00
- Author: Amilia Stone

**[AstraZeneca PLC](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l)**(
[LON:AZN](https://www.directorstalkinterviews.com/ftse-company/astrazeneca/azn.l))
has today announced that _Imfinzi_ confirmed a sustained overall survival benefit
in final analysis of the Phase III CASPIAN trial in 1st-line extensive-stage small
cell lung cancer.

High-level results from the final analysis of the Phase III CASPIAN trial showed
_Imfinzi_ (durvalumab) in combination with a choice of standard-of-care (SoC) chemotherapies
confirmed a sustained, clinically meaningful overall survival (OS) benefit for patients
with extensive-stage small cell lung cancer (ES-SCLC) treated in the 1st-line setting.

In June 2019, the CASPIAN trial met one primary endpoint for _Imfinzi_ plus SoC (
etoposide and either carboplatin or cisplatin chemotherapy) by demonstrating a statistically
significant and clinically meaningful improvement in OS versus SoC alone at a planned
interim analysis.

The second experimental arm testing tremelimumab, an anti-CTLA4 monoclonal antibody,
added to _Imfinzi_ and SoC did not meet its primary endpoint of demonstrating a 
statistically significant improvement in OS in this analysis.

> **José Baselga, AstraZeneca Executive Vice President, Oncology R&D, said: **“We
> are pleased to see the sustained and meaningful survival benefit of _Imfinzi_ 
> for patients with small cell lung cancer after more than two years median follow
> up. We have already received the first global regulatory approval for _Imfinzi_
> with etoposide plus either carboplatin or cisplatin and remain on track for more
> approvals soon as we provide patients an important new 1st-line treatment option.”

The safety and tolerability for _Imfinzi_ and tremelimumab were consistent with 
the known safety profiles of these medicines. The data will be presented at a forthcoming
medical meeting.

_Imfinzi_ in combination with etoposide and either carboplatin or cisplatin is currently
under regulatory review for the treatment of ES-SCLC in the 1st-line setting based
on the Phase III CASPIAN trial in the US, EU and Japan. The US Food and Drug Administration
has granted a Priority Review with a Prescription Drug User Fee Act date set for
the first quarter of 2020.

As part of a broad development programme, _Imfinzi_ is also being tested following
concurrent chemoradiation therapy in patients with limited-stage SCLC in the Phase
III ADRIATIC trial with data anticipated in 2021.

**Small cell lung cancer**

Lung cancer is the leading cause of cancer death among both men and women and accounts
for about one-fifth of all cancer deaths.^(1) Lung cancer is broadly split into 
non-small cell lung cancer (NSCLC) and SCLC, with about 15% classified as SCLC.^(
2) SCLC is a highly aggressive, fast-growing form of lung cancer that typically 
recurs and progresses rapidly despite initial response to chemotherapy.^(3,4) About
two thirds of SCLC patients are diagnosed with extensive-stage disease, in which
the cancer has spread widely through the lung or to other parts of the body.^(5)
Prognosis is particularly poor, as only 6% of all SCLC patients will be alive five
years after diagnosis.^(5)

**CASPIAN**

CASPIAN is a randomised, open-label, multi-centre, global, Phase III trial in the
1st-line treatment of 805 patients with ES-SCLC. The trial compared _Imfinzi_ in
combination with etoposide and either carboplatin or cisplatin chemotherapy, or 
_Imfinzi_ and chemotherapy with the addition of a second immunotherapy, tremelimumab,
versus chemotherapy alone. In the experimental arms, patients were treated with 
four cycles of chemotherapy. In comparison, the control arm allowed up to six cycles
of chemotherapy and optional prophylactic cranial irradiation. The trial was conducted
in more than 200 centres across 23 countries, including the US, in Europe, South
America, Asia and the Middle East. The primary endpoint was OS in each of the two
experimental arms.

**Imfinzi**

_Imfinzi_ (durvalumab) is a human monoclonal antibody that binds to PD-L1 and blocks
the interaction of PD-L1 with PD-1 and CD80, countering the tumour’s immune-evading
tactics and releasing the inhibition of immune responses.

_Imfinzi _is approved in the curative-intent setting of unresectable, Stage III 
NSCLC after chemoradiation therapy in the US, Japan, China, across the EU and in
many other countries, based on the Phase III PACIFIC trial. _Imfinzi_ recently received
its first global approval for the 1st-line treatment of ES-SCLC in combination with
SoC chemotherapy in Singapore. _Imfinzi_ is also approved for previously treated
patients with advanced bladder cancer in the US and a small number of other countries.

As part of a broad development programme, _Imfinzi_ is also being tested as a monotherapy
and in combination with tremelimumab, an anti-CTLA4 monoclonal antibody and potential
new medicine, as a treatment for patients with NSCLC, SCLC, bladder cancer, head
and neck cancer, liver cancer, biliary tract cancer, cervical cancer and other solid
tumours.

**Tremelimumab**

Tremelimumab is a human monoclonal antibody and potential new medicine that targets
the activity of cytotoxic T-lymphocyte-associated protein 4 (CTLA-4). Tremelimumab
blocks the activity of CTLA-4, contributing to T cell activation, priming the immune
response to cancer and fostering cancer cell death. Tremelimumab is being tested
in a clinical trial programme in combination with _Imfinzi_ in NSCLC, SCLC, bladder
cancer, head and neck cancer and liver cancer.

**References**

_1.   World Health Organization. International Agency for Research on Cancer. Available
at _[_http://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf_](http://gco.iarc.fr/today/data/factsheets/cancers/15-Lung-fact-sheet.pdf)_.
Accessed March 2020._

_2.   LUNGevity Foundation. Types of Lung Cancer. Available at _[_https://lungevity.org/for-patients-caregivers/lung-cancer-101/types-of-lung-cancer_](https://lungevity.org/for-patients-caregivers/lung-cancer-101/types-of-lung-cancer)_.
Accessed March 2020._

_3.   National Cancer Institute. NCI Dictionary – Small Cell Lung Cancer. Available
at _[_https://www.cancer.gov/publications/dictionaries/cancer-terms/def/small-cell-lung-cancer_](https://www.cancer.gov/publications/dictionaries/cancer-terms/def/small-cell-lung-cancer)_.
Accessed March 2020._

_4.   Kalemkerian GP, et al. Treatment Options for Relapsed Small-Cell Lung Cancer:
What Progress Have We Made? Journal of Oncology Practice, volume 14, issue no. 6(
June 1, 2018) 369-370._

_5.   Cancer.Net. Lung Cancer – Small Cell. Available at _[_https://www.cancer.net/cancer-types/33776/view-all_](https://www.cancer.net/cancer-types/33776/view-all)_.
Accessed March 2020._

Share on:
